BIOR: Biora Therapeutics Company Short-Term Debt

Symbol and logo of brand Progenity (BIOR)

Biora Therapeutics attracts leading engineers with ambitious tasks to create smart capsules, offering stock options and expanded insurance. Manufacturing processes rely on external contractors through strict SLA agreements. This chart on GURU.Markets, where the metric is 0.00, visualizes the asset's price action. The increase in value is driven by trials of the BioJet and NaviCap systems, as well as the search for strategic partners for the commercial launch.

BIOR (Biora Therapeutics Inc.) Company Short-Term Debts history from 04/28/2023 to 12/14/2024

Analytical breakdowns for Biora Therapeutics

- current quotes and average value forecast:
Price Chart Biora Therapeutics, Inc.|BIOR - Fair Value Consensus
- market capitalization information:
Market Value Biora Therapeutics, Inc.|BIOR - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Biora Therapeutics|BIOR - Book Capitalization|Market Cap to Net Assets Ratio bioratherapeutics.com|BIOR - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Biora Therapeutics|BIOR - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Biora Therapeutics|BIOR - Company Total Debt Obligations|Debt to Book Value Biora Therapeutics, Inc.|BIOR - Amount of Long-Term Liabilities|Company Short-Term Debts Biora Therapeutics|Quick Ratio bioratherapeutics.com
- net income and valuation multiples indicators:
BIOR - Net Financial Result
Fundamental company analysis:Biora Therapeutics, Inc. - BIOR
Manufactured products of Biora Therapeutics, Inc

Biora Therapeutics (BIOR) invests in the high-tech development of smart gastrointestinal capsules, supporting an ambitious staff of bioengineers through a system of stock options and expanded social guarantees. By analyzing the company's short-term liability structure, an investor can see the aggregate of all debts maturing within one year, which allows for an assessment of current liquidity and the risk of capital shortages amid intensive R&D expenditures.

Who Biora Therapeutics competes with

PHAT - Company Short-Term Debt|Company Short-Term Loans and Borrowings TERN (Terns Pharma)|ironwoodpharma.com (IRWD) - Company Short-Term Debt|Company Current Liabilities Curanex Pharmaceuticals|IMRN (Immuron Ltd) - Company Short-Term Debts|Company Short-Term Debts evokepharma.com|Company Current Liabilities ENTO (Entero Therapeutics, Inc.)|RDHL (redhillbio.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts PALI (Palisade Bio)|Short-Term Indebtedness Jaguar Health Corp|Morphic Holding, Inc. - Company Short-Term Debts